Dietary oxalate and intestinal inflammation: Evidence from experimental colitis and inflammatory bowel disease patient cohorts.

Authors

Anna C Salvador, Zena Khaled, Ayesh Awad, Benjamin Huan, Gwen Lau, Sophie Silverstein, David Weaver, Lee-Ching Zhu, Surekha Bantumilli, Viguna Thomas, Emanuele Baldassarri, Jace McGovern, Ezan Chaudhry, Nathan VanLandingham, Dorothy K Superdock, Brady Furey, Gloria Hayun Lee, Benjamin McMichael, Samantha Hicks, Erin C Steinbach, Matthew R Schaner, Jeremy Herzog, Leslie Garry Adams, W June Brickley, P Y Jenny Ting, Lawrence A David, David W Threadgill, Terrance S Furey, Shehzad Z Sheikh

Published in

Cellular and molecular gastroenterology and hepatology. Pages 101861. Aug 13, 2026. Epub Aug 13, 2026.

Abstract

The role of diet in the pathogenesis of the Inflammatory Bowel Diseases (IBDs) remains unclear. Most dietary interventions for IBD improve symptoms without consistent mucosal healing; exceptions include exclusive enteral nutrition and exclusion diets in Crohn's disease patients. Oxalate, a naturally occurring compound found in all plant foods, is absorbed through the gut and has been shown to activate systemic and renal pro-inflammatory immune responses. However, the impact of intestinal oxalate on innate immune response in the context of IBD is unknown.
We measured gene expression, stool oxalate content, and dietary intake in people with inflammatory bowel diseases and controls. Complementary studies were conducted in mouse models of chemically induced colitis, spontaneous colitis, and ex vivo cell culture systems to evaluate the relationships observed between oxalate transporter expression, stool oxalate content, and mucosal inflammation.
Intestinal oxalate transporters, SLC26A2 and SLC26A3 are consistently downregulated across IBD subtypes (Crohn's disease, ulcerative colitis), IBD tissues (colon, ileum), and in mouse models of experimental colitis irrespective to experimental diet assignment. In CD patients, we observed higher stool oxalate content despite variable dietary oxalate intake. Altered expression of SLC26A6 corresponded to stricturing behavior of disease in CD patients. Altered expression corresponded more directly to higher stool oxalate content and increased disease activity in mice fed an oxalate supplemented diet.
Dietary oxalate may exacerbate innate immune responses in susceptible individuals. Expression of oxalate transporters may be a disease-associated biological signal of both sensitivity to dietary oxalate and possibly, pathogenesis and clinical trajectory of IBD patients. This warrants future exploration of the role of dietary oxalate in mucosal inflammation in the IBDs.

PMID:
42595209
Bibliographic data and abstract were imported from PubMed on 14 Aug 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.